[{"orgOrder":0,"company":"University of Chicago","sponsor":"Helios Cardio","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Amiodarone Hydrochloride","moa":"HERG","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"University of Chicago \/ Helios Cardio","highestDevelopmentStatusID":"6","companyTruncated":"University of Chicago \/ Helios Cardio"}]

Find Clinical Drug Pipeline Developments & Deals for Angoron

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          University of Chicago

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          University of Chicago

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Amiodarone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Atrial Fibrillation.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 02, 2023

                          Lead Product(s) : Amiodarone Hydrochloride

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Helios Cardio

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank